SlideShare is now on Android. 15 million presentations at your fingertips.  Get the app

×
  • Share
  • Email
  • Embed
  • Like
  • Private Content
 

NeoGenomics, (Nasdaq: NEO) a fast growing cancer genetic testing lab traded on Nasdaq. February 2014 Q4 investor presentation.

by Working at Hawk Associates, Inc. on Feb 16, 2012

  • 1,587 views

NeoGenomics is the only publicly-traded pure- play cancer genetics laboratory specifically focused on high revenue cancer genetics testing. It is an emerging leader in the fastest growing segment of ...

NeoGenomics is the only publicly-traded pure- play cancer genetics laboratory specifically focused on high revenue cancer genetics testing. It is an emerging leader in the fastest growing segment of the lab testing industry, genetic/ molecular testing. Genetic/molecular testing analyzes chromosomes, genes and DNA for specific abnormalities. The company’s customers request a variety of genetics testing services that are used to confirm various types of cancer.

Statistics

Views

Total Views
1,587
Views on SlideShare
1,402
Embed Views
185

Actions

Likes
0
Downloads
8
Comments
0

5 Embeds 185

http://www.hawkassociates.com 166
https://twitter.com 11
http://editor.ne16.com 5
http://t.co 2
https://www.facebook.com 1

Accessibility

Upload Details

Uploaded via SlideShare as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
Post Comment
Edit your comment

NeoGenomics, (Nasdaq: NEO) a fast growing cancer genetic testing lab traded on Nasdaq. February 2014 Q4 investor presentation. NeoGenomics, (Nasdaq: NEO) a fast growing cancer genetic testing lab traded on Nasdaq. February 2014 Q4 investor presentation. Presentation Transcript